title: The evolving role of enzalutamide on the treatment of prostate cancer.
abstract: The field of prostate cancer has witnessed incredible progress in the last decade, owing to the approval of multiple survival-prolonging treatments for metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide is a nonsteroidal androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling axis. It has been approved for the treatment of mCRPC both in the postdocetaxel and in the chemotherapy-naive settings. We summarize the milestones in the development of enzalutamide in patients with prostate cancer. Special focus is placed on the results of the STRIVE Phase II clinical trial comparing head to head enzalutamide and bicalutamide in patients with nonmetastatic and mCRPC who have failed androgen deprivation and in other ongoing trials in the same setting and in earlier disease phases.
authors.affiliation: Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
authors.forename: Rosa
authors.initials: R
authors.lastname: Nadal
authors.affiliation: Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.
authors.forename: Joaquim
authors.initials: J
authors.lastname: Bellmunt
mesh_terms: D059002:Androgen Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy / Q000473:pathology; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D059002:Androgen Receptor Antagonists; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; D009570:Nitriles; D011944:Receptors, Androgen; D010669:Phenylthiohydantoin; C540278:enzalutamide
keywords: STRIVE; castration-resistant prostate cancer; enzalutamide; hormone-sensitive prostate cancer; prostate cancer
references.citation: N Engl J Med. 2014 Mar 6;370(10):970-1
references.pmid: 24597872
references.citation: Nat Rev Urol. 2014 Dec;11(12 ):712-6
references.pmid: 25224448
references.citation: Cancer Discov. 2013 Sep;3(9):1030-43
references.pmid: 23842682
references.citation: Ann Oncol. 2013 Jul;24(7):1802-7
references.pmid: 23585511
references.citation: Prostate. 2013 Sep;73(12):1291-305
references.pmid: 23765603
references.citation: Elife. 2013 Apr 09;2:e00499
references.pmid: 23580326
references.citation: N Engl J Med. 2012 Sep 27;367(13):1187-97
references.pmid: 22894553
references.citation: Science. 2009 May 8;324(5928):787-90
references.pmid: 19359544
references.citation: Cell. 2013 Dec 5;155(6):1309-22
references.pmid: 24315100
references.citation: N Engl J Med. 2014 Sep 11;371(11):1028-38
references.pmid: 25184630
references.citation: Cancer Res. 2015 Apr 1;75(7):1413-22
references.pmid: 25649766
references.citation: Lancet Oncol. 2013 Feb;14(2):149-58
references.pmid: 23306100
references.citation: N Engl J Med. 2015 Aug 20;373(8):737-46
references.pmid: 26244877
references.citation: Ann Oncol. 2014 Feb;25(2):429-34
references.pmid: 24478320
references.citation: Eur Urol. 2015 Nov;68(5):787-94
references.pmid: 25687533
references.citation: Eur Urol. 2015 Feb;67(2):223-30
references.pmid: 25171902
references.citation: Clin Cancer Res. 2015 May 15;21(10):2315-24
references.pmid: 25712683
references.citation: N Engl J Med. 2014 Jul 31;371(5):424-33
references.pmid: 24881730
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: Lancet. 2010 Apr 24;375(9724):1437-46
references.pmid: 20398925
references.citation: Eur J Cancer. 2014 Jan;50(1):78-84
references.pmid: 24074764
references.citation: Eur Urol. 2015 Nov;68(5):795-801
references.pmid: 25698064
references.citation: Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7
references.pmid: 25600186
references.citation: Lancet Oncol. 2014 May;15(6):592-600
references.pmid: 24739897